PULMATRIX, INC. (NASDAQ:PULM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On March 1, 2017, Scott M. Rocklage submitted his resignation as a member of the board of directors and audit committee of Pulmatrix, Inc. (the “Company”), which resignation will be effective March 13, 2017. Mr. Rocklage’s resignation was not in connection with any disagreement with the Company on any matter relating to the Company’s operations, policies or practices, or any other matter.
About PULMATRIX, INC. (NASDAQ:PULM)
Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease. PULMATRIX, INC. (NASDAQ:PULM) Recent Trading Information
PULMATRIX, INC. (NASDAQ:PULM) closed its last trading session down -0.23 at 3.93 with 737,968 shares trading hands.